Exton, Pennsylvania, Nov. 01, 2023 (GLOBE NEWSWIRE) As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has begun
Coherus BioSciences, Inc. (NASDAQ: CHRS) shares are trading higher Monday after the company announced the FDA-approval of Loqtorzi in all lines of treatment for
A survey of gastroenterologists, dermatologists, and rheumatologists found Amjevita had the most recognition, followed by Cyltezo, the only interchangeable biosimilar on the US market.